2020
Anger recall mental stress decreases 123I-metaiodobenzylguanidine (123I-MIBG) uptake and increases heterogeneity of cardiac sympathetic activity in the myocardium in patients with ischemic cardiomyopathy
Avendaño R, Hashemi-Zonouz T, Sandoval V, Liu C, Burg M, Sinusas AJ, Lampert R, Liu YH. Anger recall mental stress decreases 123I-metaiodobenzylguanidine (123I-MIBG) uptake and increases heterogeneity of cardiac sympathetic activity in the myocardium in patients with ischemic cardiomyopathy. Journal Of Nuclear Cardiology 2020, 29: 798-809. PMID: 33034036, DOI: 10.1007/s12350-020-02372-1.Peer-Reviewed Original ResearchConceptsSympathetic activityIschemic cardiomyopathyVentricular arrhythmiasICM patientsMental stressAge-matched healthy male controlsCardiac sympathetic activityHealthy control subjectsMyocardial sympathetic activityHealthy male controlsMental stress taskSPECT/CTMediastinal ratioControl subjectsHemodynamic responseAnger recallMyocardial perfusionNormal subjectsMale controlsPatientsPerfusionPsychological stressorsArrhythmiasStress taskDual-isotope imaging
2018
Early Versus Late Referral for Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease A Systematic Review and Meta-Analysis of Clinical Outcomes
Romero J, Di Biase L, Diaz J, Quispe R, Du X, Briceno D, Avendano R, Tedrow U, John R, Michaud G, Natale A, Stevenson W, Kumar S. Early Versus Late Referral for Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease A Systematic Review and Meta-Analysis of Clinical Outcomes. JACC Clinical Electrophysiology 2018, 4: 374-382. PMID: 30089564, DOI: 10.1016/j.jacep.2017.12.008.Peer-Reviewed Original ResearchConceptsStructural heart diseaseEarly referralLate referralVT ablationVentricular tachycardiaAcute complicationsVT recurrenceCatheter ablationHeart diseaseTotal mortalityLong-term VT recurrenceAcute procedural successA Systematic ReviewAcute successSecondary outcomesPrimary outcomeAntiarrhythmic drugsClinical outcomesProcedural successPatient populationWorse outcomesBetter outcomesElectronic searchPatientsReferral
2017
Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials
Romero J, Díaz J, Grushko M, Quispe R, Briceno D, Avendano R, Golive A, Pina I, Natale A, Garcia M, Jorde U, Di Biase L. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. EP Europace 2017, 20: f211-f216. PMID: 29161424, DOI: 10.1093/europace/eux324.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillatorCause mortalityNICM patientsPrimary ProphylacTic Implantable Cardioverter DefibrillatorsRole of ICDUse of ICDsTotal mortalityProphylactic implantable cardioverter defibrillatorProspective randomized clinical trialsCardiac resynchronization therapy pacemakerCause mortality benefitProphylactic ICD placementMedical therapy groupRandomized clinical trialsRandom-effects modelSignificant reductionFixed-effects modelMean followMortality benefitICD groupIschemic cardiomyopathyMedical therapyICD placementTreatment arms